Robin L. Jones, MD, MRCP
Soft tissue sarcomas may be rare, but there’s a great need for improving available treatment. That’s why Dr. Robin Jones chose this area of cancer care as his specialty.
“I saw a great opportunity to make a difference for patients with these rare diseases and Seattle Cancer Care Alliance is a great place to work toward improving existing treatments and developing new ones,” he says.
Dr. Jones is an associate professor in the Division of Medical Oncology at the University of Washington School of Medicine. His area of expertise is the care and treatment of adult bone and soft tissue sarcomas which are cancers that develop in tissues connecting, supporting or surrounding other structures and organs of the body. They are rare diseases for which the cause, in most cases, is not known.
“It was the opportunity to work with Drs. Ernest Conrad, Janet Eary, Eve Rodler, Elizabeth Loggers, Gabrielle Kane, Kit Kelly, Ben Hoch and Doug Hawkins, that attracted me to Seattle Cancer Care Alliance,” says Dr. Jones. “These are great people to work with because of their expertise and team approach."
Dr. Jones divides his time between seeing patients at the Sarcoma Clinic at SCCA and research at Fred Hutchinson Cancer Research Center.
In his practice, Dr. Jones most enjoys how every patient is different as is their disease. "It’s a challenge to get to know people, their history and to tailor their treatment to their unique needs.”
He says he can offer patients specialized care with the added benefit of having an exceptional team very accessible if needed. “We are an extremely experienced team and that can greatly enhance the quality of care and treatment, as well as the outcome for the patient.”
As a physician, he strives to have a caring attitude in his interactions with patients and to treat each person as an individual. This, he believes, is key in treating sarcomas and to ensure a more successful treatment experience.
“I’m excited to see the scope of our treatment expanding and to see the improvements in results,” Dr. Jones says. “But it happens gradually since these are really unique and rare diseases.”
Due to the rarity of sarcomas, the treatments have been broadly focused. The aim of Dr. Jones’ research is investigating sarcomas in-depth and to include all subtypes of the diseases. This, he hopes, will enable him and other researchers to eventually develop drugs designed to treat the underlying molecular drivers of these diseases. "We are using our growing understanding of the biology of these diseases to have a more targeted approach to treatment… and we are starting to see success.
“Only now are we starting to unravel the underlying molecular drivers of diseases... It’s a good time to be involved with the care and research of sarcomas and SCCA is a good place to be doing this research,” Dr. Jones says.
Outside of work, Dr. Jones enjoys spending time with his two children and participating in their activities, as well as hiking and other outdoor recreation.
Robin L. Jones, MD, MRCPDr. Jones is a medical oncologist who specializes in treating sarcomas.
Patient Care Philosophy:
My aim is to provide patients and families with high quality care in a compassionate and caring manner. It is important for patients with rare diseases to be provided with up-to-date information in order to make decisions regarding treatment. I wish to provide such information in an understandable way.
- Associate Professor, Division of Medical Oncology, University of Washington School of Medicine
- Associate Member, Fred Hutchinson Cancer Research Center
Adult bone and soft tissue sarcoma, Phase I/early clinical trials, Breast cancer
Education And Training
- Guy’s + St. Thomas’ Hospitals London
- Residency: St. Mary’s Hospital, London
- Fellowship: Royal Marsden Hospital, London
- MD (Res): Institute of Cancer Research, London
- AZD0530 for Recurrent Osteosarcoma Localized to the Lung (7008)
- Trabectedin for Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma (20051530)
- Combination Chemotherapy for Stage III-IV Malignant Peripheral Nerve Sheath Tumors (7007)
- Trabectedin or Dacarbazine Advanced L-Sarcoma (20110545)
- Eribulin or Dacarbazine for Leiomyosarcoma and Liposarcoma (UW11016)
- Pazopanib Hydrochloride Followed By Chemotherapy and Surgery for Soft Tissue Sarcoma
- TH-302 + Doxorubicin Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
- MORAb-004 + Gemcitabine and Docetaxel for Metastatic Soft Tissue Sarcoma
- Imatinib and BKM120 for 3rd Line GIST Patients